Early Phase 1 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 to 80 years old at the time of signing the consent form
- People who have been diagnosed with abnormal blood vessel growth under the retina (called choroidal neovascularization) caused by age-related macular degeneration (AMD), in the eye being studied
- People whose vision in the eye being studied falls within a specific range — roughly between 20/32 and 20/320 on a standard eye chart (confirm with trial site for exact measurement)
- People whose vision in the other eye meets a minimum level — roughly 20/400 or better on a standard eye chart
- People who are able to complete vision and retinal function tests and are willing to follow all study procedures
- People who have previously received anti-VEGF injections (a common eye treatment for AMD) and whose eye responded well to that treatment, OR people who have received anti-VEGF injections but whose eye did not respond adequately — defined as little or no improvement in retinal fluid after an initial course of treatment (confirm with trial site for exact details)
Who may not be able to join:
- People whose eye being studied has bleeding under the retina, scarring, or fibrous tissue covering more than half of the affected area
- People with any condition that, in the treating doctor's opinion, would limit the chance of vision improvement in the eye being studied
- People with other eye diseases affecting central vision in the eye being studied, such as blockage of the retinal vein, retinal detachment, a hole in the macula, or optic nerve disease
- People whose abnormal blood vessel growth is caused by something other than AMD in the eye being studied
- People with uncontrolled glaucoma in the eye being studied
- People with active inflammation inside either eye, or a history of a condition called uveitis in either eye
- People with a history or current presence of a corneal disease called corneal dystrophy in the eye being studied
- People with immune system conditions that make them prone to certain types of infections
- People who have had other eye surgery in the eye being studied within the 3 months before the study start, if the treating doctor believes it could affect healing or results
- People who have previously received gene therapy or a type of treatment called oligonucleotide therapy
- People who have had a heart attack, certain heart procedures, stroke, or mini-stroke within the 6 months before the screening visit
- People with any other condition the investigator considers unsuitable for the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, Huidagene Therapeuticd Co., Ltd.
Phone: +86 021-25076143
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of ocular and systemic adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.